BC RSV Immunoprophylaxis Program
The BC Respiratory Syncytial Virus (RSV) Immunoprophylaxis Program is a Provincial Health Services Authority program that coordinates nirsevimab RSV monoclonal antibody interventions for qualifying children under 2 years of age.
The RSV program also promotes health education to reduce RSV morbidity in BC.
The RSV program also promotes health education to reduce RSV morbidity in BC.
Learn about RSV (PDF) and nirsevimab (PDF) and find more information about RSV and prevention strategies from the BC Centre for Disease Control.
Eligibility criteria
The program has based its eligibility criteria on evidence and centred them in clinical rationale. It reviews them annually. Nirsevimab is a Health Canada-approved, long-acting monoclonal RSV blocking antibody given during the fall and winter seasons. Case surveillance by the RSV program determines when immunoprophylaxis starts and ends during the fall and winter.
For the 2025-26 season, nirsevimab is available in BC to children who are at high or moderate risk of hospitalization from RSV infection, up to 2 years of age.
Review the eligibility criteria (PDF) for the publicly funded nirsevimab program. Eligible children can receive nirsevimab in hospital or in public health settings.
Referral information
Families need a referral from a health care provider (physician or nurse) to access this program.
For patients residing in Vancouver and Richmond, health care providers can contact RSVbooking@cw.bc.ca to make a referral. For patients living in other areas of BC, please contact your health care provider for a referral.
Referring health care providers can direct questions about the program to RSV@cw.bc.ca.
Contact
BC RSV Program
BC Children’s Hospital
4480 Oak Street
Vancouver, BC
V6H 3V4
SVG
SVG
SVG
SVG
Indigenous Health
We advocate for and provide support to Indigenous patients and families who are visiting the hospital.